Skip to main content
. 2018 Feb 27;23(5):586–593. doi: 10.1634/theoncologist.2017-0479

Figure 3.

image

Genomic alteration pattern after molecular targeted therapy. The patient (see Fig. 2B) with MET Y501C was treated with cabozantinib (anti‐MET tyrosine kinase inhibitor). Repeated sequencing demonstrated reduction in levels of the MET Y501C mutation.

Abbreviations: Pre‐Tx, pretreatment; Post‐Tx, post‐treatment.